Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05594797 | Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM | recruiting | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| CD7 CAR-T Cells in T-cell Lymphoma/Leukemia |
| recruiting |
| N/A |
| 20 |
| Shenzhen University General HospitalOTHER |
| 1 |
| Nov 17, 2022 |
| clinicaltrials |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 65 | Molly GalloglyOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 28 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 289 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | not yet recruiting | Phase 1 / Phase 2 | 48 | Hellenic Society of HematologyOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05552937 | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | recruiting | Phase 2 | 50 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | recruiting | — | 100 | Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04214886 | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 24 | Loyola UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05353907 | Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma(DECIMA) | not yet recruiting | — | 78 | Guy's and St Thomas' NHS Foundation TrustOTHER | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05347641 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | not yet recruiting | Phase 2 | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05298293 | Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma(EMILY) | not yet recruiting | N/A | 160 | WepromOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03161223 | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | recruiting | Phase 1 / Phase 2 | 148 | University of VirginiaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05280626 | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP | not yet recruiting | Phase 2 | 100 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT05181501 | A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | not yet recruiting | Phase 1 | 20 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2022 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05091541 | A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 125 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 0 | Oct 25, 2021 | clinicaltrials |
| NCT04670029 | Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line(PHARAOM) | recruiting | Phase 3 | 186 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | recruiting | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05040555 | R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden | recruiting | N/A | 64 | oubai, MD/PhDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03869619 | REal World Data in LYmphoma and Survival in Adults(REALYSA) | recruiting | — | 6,000 | Hospices Civils de LyonOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04913103 | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL(CLSGMCLPOLA) | not yet recruiting | Phase 2 | 21 | Czech Lymphoma Study GroupOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT03709719 | Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia(GRAALL-QUEST) | active not recruiting | Phase 2 | 95 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma(DLBL) | not yet recruiting | Phase 1 / Phase 2 | 74 | National Health Research Institutes, TaiwanOTHER | 0 | Apr 23, 2021 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04771507 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)(IbruOnOff) | recruiting | Phase 1 / Phase 2 | 50 | Jeanette LundinOTHER | 2 | Feb 25, 2021 | clinicaltrials |
| NCT04702932 | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies(GEN-HEMO-INF) | not yet recruiting | — | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04227015 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | recruiting | Early Phase 1 | 72 | He HuangOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03356054 | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse(HOVON 136 NHL) | recruiting | Phase 1 / Phase 2 | 37 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04440436 | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | recruiting | Phase 1 / Phase 2 | 52 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 21, 2022source: clinicaltrials